| 22.07 -0.17 (-0.76%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 26.9 | 1-year : | 29.09 |
| Resists | First : | 23.03 | Second : | 24.9 |
| Pivot price | 21.65 |
|||
| Supports | First : | 20 | Second : | 16.63 |
| MAs | MA(5) : | 22.14  |
MA(20) : | 22.04 |
| MA(100) : | 22.13 |
MA(250) : | 15.48 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.2 |
D(3) : | 63 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 26.39 | Low : | 6.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RCUS ] has closed below upper band by 36.8%. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.34 - 22.46 | 22.46 - 22.56 |
| Low: | 21.3 - 21.45 | 21.45 - 21.57 |
| Close: | 21.84 - 22.07 | 22.07 - 22.27 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Mon, 06 Apr 2026
Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation - MSN
Thu, 02 Apr 2026
RCUS: Wedbush Raises Price Target for Arcus Biosciences | RCUS S - GuruFocus
Wed, 01 Apr 2026
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Fri, 27 Mar 2026
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound - simplywall.st
Tue, 24 Mar 2026
Two new hires get Arcus stock awards priced at $21.41 a share - Stock Titan
Mon, 23 Mar 2026
COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 125 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 29.4 (%) |
| Held by Institutions | 74.4 (%) |
| Shares Short | 8,610 (K) |
| Shares Short P.Month | 9,010 (K) |
| EPS | -3.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.03 |
| Profit Margin | -143 % |
| Operating Margin | -345.5 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | -63.3 % |
| Qtrly Rev. Growth | 26.8 % |
| Gross Profit (p.s.) | -2.21 |
| Sales Per Share | 1.97 |
| EBITDA (p.s.) | -3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -482 (M) |
| Levered Free Cash Flow | -162 (M) |
| PE Ratio | -6.71 |
| PEG Ratio | 0 |
| Price to Book value | 4.37 |
| Price to Sales | 11.2 |
| Price to Cash Flow | -5.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|